In light of a U.S. methotrexate shortage, Hospira began shipping 31,000 vials of 1g methotrexate to U.S. hospitals and treatment centers on Monday, enough for one month’s U.S. demand. In addition, Hospira continues to work closely with the FDA to ensure that by mid-March the company will have produced enough supply of methotrexate for the full year.

Methotrexate is an injectable drug used to treat a variety of cancerous and rheumatologic conditions, including acute lymphoblastic leukemia (ALL).

For more information, visit www.hospira.com.